17789-14-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-BROMOPHENYL)-1,3-DIOXOLANE is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new molecules with potential therapeutic applications.
Used in Chemical Synthesis:
2-(3-BROMOPHENYL)-1,3-DIOXOLANE is used as a key component in the synthesis of acetal by arylation of 1-benzylpiperidin-4-amine. This process demonstrates its utility in creating complex organic molecules for further research and development.

InChI:InChI=1/C10H11BrO2/c11-9-4-1-3-8(7-9)10-12-5-2-6-13-10/h1,3-4,7,10H,2,5-6H2

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 107-21-1 ethylene glycol 
• 7381-30-8 2,2,7,7-tetramethyl-3,6-dioxa-2,7-disilaoctane 
• 646-06-0 1,3-DIOXOLANE 
• 89598-96-9 (3-bromophenyl)boronic acid 

Downstream Products

• 619-21-6 m-formylphenyl benzoic acid 
• 19693-78-8 2-(3-methoxyphenyl)-1,3-dioxolane 
• 59276-28-7 m-anisaldehyde dimethyl acetal 
• 123-11-5 4-methoxy-benzaldehyde 
• 591-31-1 3-methoxy-benzaldehyde 
• 135-02-4 ortho-anisaldehyde 

Relevant academic research and scientific papers

Visible-Light Mediated Oxidative Fragmentation of Ethers and Acetals by Means of Fe(III) Catalysis

A new method employing iron(III) acetylacetonate along with visible light is described to effect oxidative ring opening of cyclic ethers and acetals with unparalleled efficiency. The method allows for a photocatalytic radical chemistry approach to functionalize relatively inert cyclic ethers into useful synthetic intermediates. The methodology sheds further light on the use of underexplored iron complexes in visible-light photochemical contexts and illustrates that simple Fe(III) complexes can initiate redox processes from 4LMCT excited states.

SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO TDP-43, ALPHA-SYNUCLEIN, HUNTINGTIN'S PROTEIN AND TAU PROTEIN OLIGOMER FORMATION

The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of certain types of oligomers in a subject. More specifically, the drugs and compositions reduce or prevent the formation of oligomers formed from tau protein, TDP-43, Huntingtin's protein and/or alpha- synuclein. It further provides a method of reducing formation of or disrupting TDP-43, alpha- synuclein, Huntingtin's protein and/or tau protein oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.

MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE

The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin such as sickle cell disease.

Ni-Catalyzed Reductive Cyanation of Aryl Halides and Phenol Derivatives via Transnitrilation

Herein, we report a Ni-catalyzed reductive coupling for the synthesis of benzonitriles from aryl (pseudo)halides and an electrophilic cyanating reagent, 2-methyl-2-phenyl malononitrile (MPMN). MPMN is a bench-stable, carbon-bound electrophilic CN reagent that does not release cyanide under the reaction conditions. A variety of medicinally relevant benzonitriles can be made in good yields. Addition of NaBr to the reaction mixture allows for the use of more challenging aryl electrophiles such as aryl chlorides, tosylates, and triflates. Mechanistic investigations suggest that NaBr plays a role in facilitating oxidative addition with these substrates.

Ni-Catalyzed Site-Selective Dicarboxylation of 1,3-Dienes with CO2

A site-selective catalytic incorporation of multiple CO2 molecules into 1,3-dienes en route to adipic acids is described. This protocol is characterized by its mild conditions, excellent chemo- and regioselectivity and ease of execution under CO2 (1 atm), including the use of bulk butadiene and/or isoprene feedstocks.

Synthesis of Tetranuclear Palladium(II) Complexes and Their Catalytic Activity for Cross-Coupling Reactions

We have developed a short and simple synthesis of tetranuclear palladium(II) complexes that have been structurally confirmed by X-ray analysis. These complexes were formed in about 30 % overall yield by spontaneous metalation of dimethylaminoarene derivatives and exhibit a high stability. We have studied the utility of the tetranuclear palladium(II) complexes as precatalysts for Mizoroki–Heck and Suzuki–Miyaura cross-coupling reactions. Our novel complexes show excellent catalytic activities with high turnover numbers (TON) and high turnover frequencies (TOF) (e.g., for the Suzuki–Miyaura reaction: TON up to 538000 and TOF up to 23400 h?1 at room temperature).

Base Catalysis Enables Access to α,α-Difluoroalkylthioethers

A nucleophilic addition reaction of aryl thiols to readily available β,β-difluorostyrenes provides α,α-difluoroalkylthioethers. The reaction proceeds through an unstable anionic intermediate, prone to eliminate fluoride and generate α-fluorovinylthioethers. However, the use of base catalysis overcomes the facile β-fluoride elimination, generating α,α-difluoroalkylthioethers in excellent yields and selectivities.

A centre silicon chiral silane derivatives

The invention discloses a silicon chiral center silane derivative, which has a general formula shown as a formula (II), and a preparation method thereof. The silicon chiral center silane derivative provided by the invention has very high optical purity (>99%), can be applied to chiral molecule synthesis as a chiral ligand, especially to fields of resource chemistry and fine chemical engineering as a chiral ligand or a key intermediate.

Chemo- and Enantioselective Addition and β-Hydrogen Transfer Reduction of Carbonyl Compounds with Diethylzinc Reagent in One Pot Catalyzed by a Single Chiral Organometallic Catalyst

Using a single chiral phosphoramide-Zn(II) complex as the catalyst, the asymmetric β-H transfer reduction of aromatic α-trifluoromethyl ketones and enantioselective addition of aromatic aldehydes with Et2Zn in one pot were successfully realized, affording the corresponding additive products of secondary alcohols in high yields (up to 99%) with excellent enantioselectivities (up to 98% ee) and the reduction products of α-trifluoromethyl alcohols in good to excellent yields with up to 77% ee.

Acetalization of aldehydes and ketones over H4[SiW 12O40] and H4[SiW12O 40]/SiO2

H4[SiW12O40] (H-SiW12) is demonstrated to be able to efficiently catalyze the acetalization of aldehydes and ketones with ethylene glycol and 1,3-propanediol. Nevertheless, the possible leaching and the recycling of H-SiW12 are two major disadvantages that largely restrict its further application in industry. Moreover, H 4[SiW12O40] tends to deactivate strong proton sites due to the small surface area of 10 m2 g-1. Due to interactions with surface silanol groups, the proton sites of polyoxometalates (POMs) on SiO2 are less susceptible to deactivation. As such, immobilization of H4[SiW12O40] onto SiO 2 leads to the heterogeneous catalyst H4[SiW 12O40]/SiO2 (H-SiW12/SiO 2), which can catalyze the acetalization of aldehydes and ketones with ethylene glycol and 1,3-propanediol selectively and efficiently without the need of a drying agent. The acetalization process can proceed smoothly at a relatively low temperature under solvent-free conditions. The catalyst of H 4[SiW12O40]/SiO2 can be recycled at least ten times without an obvious decrease in its catalytic activity. As far as we know, the TONs of the H-SiW12/SiO2-catalyzed acetalization of cyclohexanone with ethylene glycol, and benzaldehyde with 1,3-propanediol are the highest reported so far.